The Positive Effects of One-Hour Intravenous Administration of Bortezomib on Peripheral Neuropathy in Multiple Myeloma Patients

Table 2

Treatment exposure.

	𝑁=23
Regimen
VMP	13 (57)
VD	8 (35)
PAD	1 (4)
Bortezomib	1 (4)
Number of treatment cycles	5 (2–10)
Time on treatment (weeks)	19 (7–54)
Bortezomib cumulative dose (mg/m^2)	26.0 (14.3–66.3)
Bortezomib dose intensity (mg/m^2/cycle)	6.5 (2.6–10.4)
Bortezomib real/expected cumulative dose (%)	90 (50–100)
Cause of treatment cessation
Progressive disease	7 (31)
Adverse events except peripheral neuropathy	5 (22)
Insurance reimbursement issue	4 (17)
On treatment	3 (13)
Patients refusal	3 (13)
Preplanned cycles	1 (4)

Data are median (range) or number (%). VMP: bortezomib, melphalan, and dexamethasone, VD: bortezomib and dexamethasone, and PAD: bortezomib, doxorubicin, and dexamethasone.